The short version of chronic hepatitis B fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
a known amount of anti-HbA1c antibody is added to the sample because only one binding site is available per HbA1c molecule (the glycated N-terminal valine on a beta chain), the antibody-HbA1c complex is small and soluble excess polyhapten is added to the sample. The polyhapten is several HbA1c-like epitopes bound together excess antibody cross-links with the polyhapten and forms large complexes which are insoluble and make the solution turbid Turbidity is inversely proportional to HbA1c concentration Concentration of HbA1c divided by concentration of total Hb (e.g. measured by absorptiometry) gives a percentage HbA1c
Chemical ionization (CI) is a lower energy process than electron ionization because it involves ion/molecule reactions rather than electron removal. The lower energy yields less fragmentation and usually a simpler spectrum. A typical CI spectrum has an easily identifiable molecular ion. In a CI experiment, ions are produced through the collision of the analyte with ions of a reagent gas in the ion source. Some common reagent gases include methane, ammonia, and isobutane. Inside the ion source, the reagent gas is present in large excess compared to the analyte. Electrons entering the source will preferentially ionize the reagent gas. The resultant collisions with other reagent gas molecules will create an ionization plasma. Positive and negative ions of the analyte are formed by reactions with this plasma. For example, protonation occurs by
=== Absorption === Absorption refrigerators may be used in caravans and trailers, and dwellings lacking electricity, such as farms or rural cabins, where they have a long history. They may be powered by any heat source: gas (natural or propane) or kerosene being common. Models made for camping and RV use often have the option of running (inefficiently) on 12 volt battery power.
Sources: en.wikipedia.org
Fast CFDs of advanced designs have the dead times equal to or less than two single-hit response times of the ion detector (single-hit response time for MCP with 2-5 micron wide channels can be somewhere between 0.2 ns and 0.8 ns, depending on the channel angle) thus preventing repetitive triggering from the same pulse. Double-hit resolution (dead time) of modern multi-hit TDC can be as low as 3-5 nanosecond. The TDC is a counting detector – it can be extremely fast (down to a few picosecond resolution), but its dynamic range is limited due to its inability to properly count the events when more than one ion simultaneously (i.e., within the TDC dead time) hit the detector. The outcome of limited dynamic range is that the number of ions (events) recorded in one mass spectrum is smaller compared to real number. The problem of limited dynamic range can be alleviated using multichannel detector design: an array of mini-anodes attached to a common MCP stack and multiple CFD/TDC, where each CFD/TDC records signals from individual mini-anode. To obtain peaks with statistically acceptable intensities, ion counting is accompanied by summing of hundreds of individual mass spectra (so-called hystograming). To reach a very high counting rate (limited only by duration of individual TOF spectrum which can be as high as few milliseconds in multipath TOF setups), a very high repetition rate of ion extractions to the TOF tube is used. Commercial orthogonal acceleration TOF mass analyzers typically operate at 5–20 kHz repetition rates.
Adsorption refrigeration also uses a thermally driven sorption process, but the refrigerant is taken up by a solid adsorbent rather than dissolved in a liquid absorbent. Common adsorption working pairs include water with silica gel or zeolite, and methanol with activated carbon. In a basic adsorption cycle, heating the adsorbent releases refrigerant vapour, which is condensed. When the adsorbent is subsequently cooled, it adsorbs refrigerant vapour again; evaporation of the refrigerant during this part of the cycle produces the cooling effect. Adsorption systems can be driven by low-grade heat sources, including solar or waste heat. Adsorption refrigeration has been extensively studied as an alternative to conventional vapor-compression cooling. Reviews have noted advantages such as the potential use of low-grade thermal energy and relatively simple solid-sorbent systems, while also identifying limitations including comparatively low performance and continuing technical and economic challenges. The main difference from absorption cycle is that in adsorption cycle, the refrigerant (adsorbate) can be ammonia, water, methanol, etc., while the adsorbent is a solid, such as silica gel, activated carbon, or zeolite, while in the absorption cycle the absorbent is liquid. The reason adsorption refrigeration technology has been extensively researched in recent 30 years lies in that the operation of an adsorption refrigeration system is often noiseless, non-corrosive and environmentally friendly.
== Premise == Set in Plainfield, Indiana, the series follows Ms. Pat's fictional family, the Carsons: Pat (Ms. Pat); her husband Terry (J. Bernard Calloway); her sister Denise (Tami Roman); and Pat's children Ashley (Brittany Inge); Brandon (Vince Swann); Janelle (Briyana Guadalupe); and Junebug (Theodore John Barnes). Pat sometimes struggles to adjust with the changing times and ways of her conservative Indiana town after moving there from her Atlanta, Georgia, hometown. Although blunt and sometimes hardheaded, Pat loves her family and her open-mindedness helps her succeed as a Black woman in a suburban white neighborhood.
Sources: en.wikipedia.org
Fibrous papules are also termed facial angiofibromas and were formerly and incorrectly termed adenoma sebaceum (fibrous papules are unrelated to sebaceous glands). They develop in up to 8% of the general adult population and occur as 1 to 3 pink to red, dome-shaped papules in the central areas of the face, nose, and/or lips. About 75% of individuals with tuberous sclerosis present with fibrous papules in their infancy or early childhood; when associated with this rare disease, the lesions often occur as multiple papules in symmetrical, butterfly-shaped patterns over both cheeks and the nose. Fibrous papules also occur in individuals with multiple endocrine neoplasia type 1 (a study done in Japan found that 43% of individuals with this genetic disease bore facial angiofibromas) and, uncommonly, in individuals with Birt-Hogg-Dube syndrome.
== History == Mirtazapine was first synthesized at Organon and published in 1989, was first approved for use in major depressive disorder in the Netherlands in 1994, and was introduced in the United States in 1996 under the brand name Remeron.
According to the assessment, he had a "pervasive tendency to demean, humiliate others and violate their rights and feelings", and was "unable to reflect on the consequences of his actions." In a speech to the Filipino community in Russia, Duterte revealed that he has myasthenia gravis, a neuromuscular disease, which makes his eye droop.
Ultrasound is routinely used in the evaluation of cirrhosis. It may show a small and shrunken liver in advanced disease. On ultrasound, there is increased echogenicity with irregular appearing areas. Other suggestive findings are an enlarged caudate lobe, liver surface nodularity widening of the fissures and enlargement of the spleen. An enlarged spleen, which normally measures less than 11–12 cm (4.3–4.7 in) in adults, may suggest underlying portal hypertension. Ultrasound may also screen for hepatocellular carcinoma and portal hypertension. This is done by assessing flow in the hepatic vein. An increased portal vein pulsatility may be seen. However, this may be a sign of elevated right atrial pressure. Portal vein pulsatility is usually measured by a pulsatility index (PI). A number above a certain value indicates cirrhosis (see table below).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.